

ASX RELEASE

Trading Update – Operational initiatives on track, AUD revaluation in H2 likely to impact FY26 Result

Key points

- H2 FY26 Market demand aligned with projections.
- Successful execution of cost/margin initiatives.
- Appreciation of the Australian dollar (AUD) likely to impact reported results circa \$4.0M in Revenue and \$2.0M in nEBITDA.
- Forex hedging practice through to June 2027 protects cash position.
- Final step in global ERP roll-out underway.

27 May 2026 – Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has today issued a trading update to shareholders:

The market demand for Trajan products has remained on trend and generally in line with expectations. Overall, the business continues to show growth on a fixed forex basis. By Segment: Components and Consumables aligned with long-term trends; growth in the Capital Equipment order book; and accelerated growth in Disruptive Technologies, have been observed.

Trajan maintains its enduring key partnerships with loyal blue-chip customers and operates with stability and resilience during a period of global economic change and ongoing global conflicts. This is strengthened with our “in region for region” manufacturing strategy.

As communicated to investors in March 2026, the realisation of cost/margin improvements tied to project “Neptune” are ongoing. In our unaudited management accounts, we are seeing a positive impact in H2, including headcount reductions (\$0.8M+ in the half), and completion of the first step in rationalising our global footprint with a reduction in ongoing facility costs in our Connecticut Operations.

As reported in February 2026, it is likely that an appreciation of the Australian dollar against both the USD and EUR will affect the translation of results from Trajan’s overseas operations during H2 FY26. After more than 2 years of foreign currency stability there has been a

strengthening of the AUD against key overseas reporting currencies since the H1 FY26 results announcement. At current rates H2 FY26 reported results could be impacted by the recent changes by circa \$4.0M in Revenue and \$2.0M in nEBITDA

While Trajan's cash position is protected against such movement in the AUD/USD due to the substantial foreign exchange hedging contracts in place through to June 2027, those benefits, and other non-cash FX impacts, are excluded from the reported nEBITDA results.

Since IPO our AUD exposure has continued to reduce due to project Neptune; by installing automation in Australia and the US and by redirecting a significant proportion of our operations into Malaysia. In addition, business acquisitions since IPO, outside of Australia, have also provided further natural hedging against shifting FX rates.

Operational changes late in 2H FY26 include the roll-out of a new ERP system in Germany which aligns with our global system and will greatly improve supply chain management offering future efficiency gains. As the team works through this major initiative, it poses a potential risk to the timing of capital equipment shipments and revenue recognition as we near the end of FY26.

CEO Stephen Tomisich shared that:

“Operationally Trajan has largely performed as expected in H2 FY26. The anticipated productivity and margin gains are being realised, growth in our Components and Consumables Segment has continued on trend and the accelerated growth of our Disruptive Technologies Segment is starting to demonstrate the value of these long-term investments. The Capital Equipment order book has remained strong and meeting full year revenue targets will again be very much about what can be shipped and recognised prior to year end”

Authorised for ASX release by the Disclosure Committee of Trajan Group Holdings Limited

END



Trajan Scientific and Medical

Global Corporate Headquarters
7 Argent Place, Ringwood
Victoria 3134, Australia
Tel: +61 (0) 3 9837 4200
www.trajanscimed.com

Trajan Group Holdings Limited
ACN 152 617 706

Contact:

Investors

investorrelations@trajanscimed.com

Media

media@trajanscimed.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.

For personal use only